Surgery versus stereotactic body radiation therapy for stage I non-small cell lung cancer: A comprehensive review.

Published

Journal Article (Review)

Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related death in the United States. With the implementation of lung cancer screening, the number and proportion of patients diagnosed with early-stage disease are anticipated to increase. Surgery is currently the standard of care for patients with operable stage I NSCLC. However, promising outcomes with stereotactic body radiation therapy (SBRT) in patients with inoperable disease has led to interest in directly comparing SBRT and surgery in operable patients. Unfortunately, early randomized trials comparing surgery and SBRT closed early because of poor accrual. In this article, the nuances of surgery and SBRT for early-stage NSCLC are reviewed. Furthermore, retrospective and prospective analyses of SBRT in early-stage NSCLC are discussed, and active randomized trials comparing these 2 approaches are described. Cancer 2018;124:667-78. © 2017 American Cancer Society.

Full Text

Duke Authors

Cited Authors

  • Tandberg, DJ; Tong, BC; Ackerson, BG; Kelsey, CR

Published Date

  • February 15, 2018

Published In

Volume / Issue

  • 124 / 4

Start / End Page

  • 667 - 678

PubMed ID

  • 29266226

Pubmed Central ID

  • 29266226

Electronic International Standard Serial Number (EISSN)

  • 1097-0142

Digital Object Identifier (DOI)

  • 10.1002/cncr.31196

Language

  • eng

Conference Location

  • United States